These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

508 related items for PubMed ID: 12412170

  • 1. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA, Wood L, Hsi E, Srkalovic G, Karam M, Elson P, Bukowski RM.
    Cancer; 2002 Nov 15; 95(10):2160-8. PubMed ID: 12412170
    [Abstract] [Full Text] [Related]

  • 2. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA.
    Cancer; 2006 Feb 15; 106(4):848-58. PubMed ID: 16404741
    [Abstract] [Full Text] [Related]

  • 3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
    Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.
    Srp Arh Celok Lek; 1996 Feb 15; 124(11-12):292-6. PubMed ID: 9132962
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma.
    Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS.
    J Clin Oncol; 2009 Oct 20; 27(30):5015-22. PubMed ID: 19738129
    [Abstract] [Full Text] [Related]

  • 5. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.
    Eur J Haematol; 2007 Apr 20; 78(4):297-302. PubMed ID: 17286608
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
    Leighl NB, Goss GD, Lopez PG, Burkes RL, Dancey JE, Rahim YH, Rudinskas LC, Pouliot JF, Rodgers A, Pond GR, Shepherd FA.
    Lung Cancer; 2006 Jun 20; 52(3):327-32. PubMed ID: 16597474
    [Abstract] [Full Text] [Related]

  • 7. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G, Clark RE, Morris TC, Robertson M, Lucie NP, Anderson S, Paul J, Franklin IM.
    Br J Haematol; 2004 Sep 20; 126(6):792-8. PubMed ID: 15352982
    [Abstract] [Full Text] [Related]

  • 8. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
    Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, Galieni P, Catarini M, Burattini M, Centurioni R, Rupoli S, Scortechini AR, Giuliodori L, Candela M, Capelli D, Montanari M, Olivieri A, Piersantelli MN, Leoni P.
    Haematologica; 2006 Jan 20; 91(1):133-6. PubMed ID: 16434383
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
    Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, Hayman S, Fonseca R, Lust JA, Kyle RA, Greipp PR, Witzig TE.
    Haematologica; 2005 Dec 20; 90(12):1650-4. PubMed ID: 16330438
    [Abstract] [Full Text] [Related]

  • 10. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group.
    Cancer; 2008 Jan 01; 112(1):129-35. PubMed ID: 17973267
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, Spicka I, Sutherland HJ, Suvorov AN, Zhuang SH, Parekh T, Xiu L, Yuan Z, Rackoff W, Harousseau JL.
    J Clin Oncol; 2007 Sep 01; 25(25):3892-901. PubMed ID: 17679727
    [Abstract] [Full Text] [Related]

  • 12. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
    Ciolli S, Leoni F, Casini C, Breschi C, Santini V, Bosi A.
    Br J Haematol; 2008 Jun 01; 141(6):814-9. PubMed ID: 18410447
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of CLAD (cyclophosphamide, liposomal doxorubicin and dexamethasone) in patients with advanced multiple myeloma and historical comparison to CAD (cyclophosphamide, doxorubicin and dexamethasone).
    Hütter G, Szélenyi H, Schmittel A, Siehl JM, Thiel E, Keilholz U.
    Hematol Oncol; 2007 Sep 01; 25(3):132-9. PubMed ID: 17514772
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
    Yuan ZG, Hou J, Wang DX, Fu WJ, Chen YB, Xi H.
    Ai Zheng; 2007 Dec 01; 26(12):1369-72. PubMed ID: 18076804
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma.
    Porter CA, Rifkin RM.
    Clin Lymphoma Myeloma; 2007 Apr 01; 7 Suppl 4():S150-5. PubMed ID: 17562253
    [Abstract] [Full Text] [Related]

  • 16. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.
    Bone Marrow Transplant; 1999 Feb 01; 23(4):317-22. PubMed ID: 10100574
    [Abstract] [Full Text] [Related]

  • 17. A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.
    Berenson JR, Yellin O, Chen CS, Patel R, Bessudo A, Boccia RV, Yang HH, Vescio R, Yung E, Mapes R, Eades B, Hilger JD, Wirtschafter E, Hilger J, Nassir Y, Swift RA.
    Br J Haematol; 2011 Dec 01; 155(5):580-7. PubMed ID: 21950583
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O, Hubert A, Gabizon AA.
    Clin Cancer Res; 2001 Oct 01; 7(10):3040-6. PubMed ID: 11595693
    [Abstract] [Full Text] [Related]

  • 19. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
    Trudeau ME, Clemons MJ, Provencher L, Panasci L, Yelle L, Rayson D, Latreille J, Vandenberg T, Goel R, Zibdawi L, Rahim Y, Pouliot JF.
    J Clin Oncol; 2009 Dec 10; 27(35):5906-10. PubMed ID: 19858391
    [Abstract] [Full Text] [Related]

  • 20. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.
    Am J Clin Oncol; 2008 Oct 10; 31(5):476-80. PubMed ID: 18838885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.